Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07627698CT.gov Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | — | Recruiting | — | — | — |
NCT06626256CT.gov STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | — | Withdrawn | — | — | — |
NCT06961357CT.gov Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | — | Recruiting | — | — | — |
NCT06204991CT.gov To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | — | Recruiting | — | — | — |
NCT06889766CT.gov NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma | — | Recruiting | — | — | — |
NCT06630611CT.gov Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) | — | Recruiting | — | — | — |
NCT06190249CT.gov Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | — | Withdrawn | — | — | — |
NCT06237881CT.gov A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06151847CT.gov Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT06060613CT.gov Safety and Efficacy of OBX-115 in Advanced Solid Tumors | — | Recruiting | — | — | — |
Show 39 more trialsShow fewer
NCT05628883CT.gov Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | — | Completed | — | — | — |
NCT05470283CT.gov Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05361174CT.gov A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | — | Recruiting | — | — | — |
NCT04897321CT.gov B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | — | Recruiting | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT05296564CT.gov Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | — | Recruiting | — | — | — |
NCT04904185CT.gov ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT04596033CT.gov TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | — | Terminated | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03399448CT.gov NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | — | Terminated | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03158935CT.gov The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | — | Completed | — | — | — |
NCT03166397CT.gov Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | — | Unknown | — | — | — |
NCT02830724CT.gov Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | — | Recruiting | — | — | — |
NCT02869217CT.gov Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02621021CT.gov A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | — | Recruiting | — | — | — |
NCT02457650CT.gov T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | — | Unknown | — | — | — |
NCT02153905CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | — | Terminated | — | — | — |
NCT02111863CT.gov Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT02111850CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | — | Completed | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
NCT01946373CT.gov T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | — | Unknown | — | — | — |
NCT01625351CT.gov A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | — | Completed | — | — | — |
NCT01585415CT.gov Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | — | Terminated | — | — | — |
NCT01339663CT.gov Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00945269CT.gov Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT00937625CT.gov T-cell Based Immunotherapy for of Melanoma | — | Completed | — | — | — |
NCT00923195CT.gov Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00553306CT.gov Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00924001CT.gov Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | — | Terminated | — | — | — |
NCT00509288CT.gov Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes | — | Completed | — | — | — |
NCT00513604CT.gov Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT00509496CT.gov Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | — | Terminated | — | — | — |
NCT00438984CT.gov Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00338377CT.gov Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT00303836CT.gov Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT00001832CT.gov Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | — | Completed | — | — | — |
NCT00003552CT.gov Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Beijing Biotech | P2 | B · 62 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →